Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib plus Atezolizumab in Newly Diagnosed CML
NCT04793399Phase 2Terminated
- Sponsor
- Fundación Española para la Curación de la Leucemia Mieloide Crónica
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in chronic myeloid leukemia (CML), sponsored by Fundación Española para la Curación de la Leucemia Mieloide Crónica. Started Feb 2021; status: terminated.
02
Drugs
atezolizumab
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04793399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793399.